CalciMedica, Inc. Price & Performance (CALC)

CalciMedica has secured a $32.5 million credit facility, with $10 million available immediately. This funding extends the company’s cash runway into mid-2026, supporting its clinical pipeline, including the Phase 2 KOURAGE trial. The funds will also aid in discussions with the FDA for a Phase 3 program targeting acute pancreatitis.1

Graybug Vision's stock has hit a 52-week low, trading at $1.83. The company faces ongoing challenges, with its financial and operational hurdles causing investor concerns. This decline reflects broader struggles in the biotech sector, particularly for smaller firms navigating high costs and competitive pressures.23

Atria Investments has boosted its stake in CalciMedica by 28.3%, acquiring an additional 7,509 shares. This investment brings Atria’s total holdings to 34,012 shares, valued at $120,000. The move indicates growing confidence in CalciMedica’s potential amid its ongoing clinical trials and drug development efforts.4